Cas:757-17-5 1,1,2,2-tetrafluoro-1-(2-methoxyethoxy)ethane manufacturer & supplier

Chemical Name:1,1,2,2-tetrafluoro-1-(2-methoxyethoxy)ethane

CAS.NO:757-17-5

Synonyms:1-METHOXY-2-(1,1,2,2-TETRAFLUOROETHOXY)ETHANE;Aethylenglykol-methylaether-<1,1,2,2-tetrafluor-aethylaether>;EINECS 212-054-4

Molecular Formula:C₅H₈F₄O₂

Molecular Weight:176.10900

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:117ºC

Density:1.206

Index of Refraction:1.3317

PSA:18.46000

Exact Mass:176.04600

LogP:1.50730

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-METHOXY-2-(1,1,2,2-TETRAFLUOROETHOXY)ETHANE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 212-054-4 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 212-054-4 Use and application,1,1,2,2-tetrafluor-aethylaether&gt technical grade,usp/ep/jp grade.

Related News: Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. 1,1,2,2-tetrafluoro-1-(2-methoxyethoxy)ethane manufacturer Catalent, a global leader in clinical supply services, recently announced the launch of its new CTSuccessTM clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress. 1,1,2,2-tetrafluoro-1-(2-methoxyethoxy)ethane supplier Fate Therapeutics has exclusively licensed from MSK foundational intellectual property covering the production and composition of iPSC-derived T cells. 1,1,2,2-tetrafluoro-1-(2-methoxyethoxy)ethane vendor Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. 1,1,2,2-tetrafluoro-1-(2-methoxyethoxy)ethane factory Catalent, a global leader in clinical supply services, recently announced the launch of its new CTSuccessTM clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress.